ARCHIVES

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

This article is from The Cancer Letter archive.

Vol. 36 No. 09 | March 12, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Cancer Act Renewals Marked By Disputes Over NCI Authorities

October 5, 1990

In Brief: Cancer Program “Strengthened” NIH, Report From Biomedical Research Panel Contends

April 16, 1976

Revlimid Shows 91 Percent Response in Non-Hodgkin’s

July 29, 2011

Basic Research Group Seeks $7.9 Billion For NIH, $1.7 For NCI

July 24, 1987

NIH Chemical Genomics Center to screen small molecules.

June 18, 2004